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Abstract
Pyrrole-imidazole (Py-Im) polyamides are a class of programmable DNA minor groove binders
capable of modulating the activity of DNA-binding proteins and affecting changes in gene
expression. Estrogen Receptor Alpha (ERα) is a ligand-activated hormone receptor that binds as a
homodimer to estrogen response elements (EREs) and is a driving oncogene in a majority of
breast cancers. We tested a selection of structurally similar Py-Im polyamides with differing DNA
sequence specificity for activity against 17β-estadiol (E2) induced transcription and cytotoxicity in
ERα positive, E2 stimulated T47D-KBLUC cells, which express luciferase under ERα control.
The most active polyamide targeted the sequence: 5’-WGGWCW-3’ (W = A or T), which is the
canonical ERE-half site. Whole transcriptome analysis using RNA-Seq revealed that treatment of
E2-stimulated breast cancer cells with this polyamide reduced the effects of E2 on the majority of
those most strongly affected by E2, but had much less effect on the majority of E2 induced
transcripts. In vivo, this polyamide circulated at detectable levels following subcutaneous injection
and reduced levels of ER-driven luciferase expression in xenografted tumors in mice after
subcutaneous compound administration without significant host toxicity.
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Introduction
Estrogen receptor alpha (ERα) is a member of the nuclear hormone receptor family of
transcription factors and is active in a majority of breast adenocarcinomas (1, 2). Breast
tumors that express ERα and are sensitive to circulating estrogens respond to therapeutics
that modulate ERα activity (3). Such therapeutics include tamoxifen, a selective estrogen
receptor modulator that acts as a weak agonist/antagonist by binding to the ERα ligand
binding pocket, and the aromatase inhibitors that inhibit synthesis of E2 (3). A different
strategy for modulation of ERα activity is inhibition of the ERα-ERE interface by a DNA-
binding molecule.
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Py-Im polyamides are a class of synthetic, minor groove binding ligands inspired by the
natural product distamycin A (4, 5). Py-Im polyamides are oligomers of aromatic amino
acids linked in series to fold in an anti-parallel fashion when bound in the minor groove of
DNA (4, 5). Sequence specificity is programmed through side-by side pairings of the Py and
Im subunits that recognize differences in the shape and hydrogen bonding pattern presented
by the edges of the Watson Crick base pairs in the floor of the minor groove (6, 7). Binding
specificity has been extensively characterized by DNAse I footprinting titrations and other
methods. An Im:Py pair preferentially recognizes G:C; Py:Im prefers C:G, and Py:Py is
degenerate for A:T and T:A (6, 7). Py-Im polyamide binding in the minor groove also
induces allosteric changes to the major groove (8, 9) and binding affinity is sufficient to
modulate the binding of DNA-binding proteins (8–11).
In cell culture, selected polyamides have been used to modulate expression of genes induced
by testosterone (11), TNF-alpha (12), hypoxia (13, 14), and dexamethasone (10). The
mechanisms by which polyamides affect gene expression changes in cell culture is still not
well understood and may involve direct effects on multiple DNA-dependent processes
including transcription factor occupancy, chromatin structure, RNA polymerases, and DNA
replication (15). The pharmacokinetics and toxicity of a number of polyamides after
intravenous and subcutaneous injection in mice and rats have been described (16–18). In
mice, a selected polyamide was reported to induce changes in TGF-beta expression in
kidney glomeruli, and a fluorescent analog of this polyamide was observed in kidney
glomeruli after tail vein injection in rats (19). Gene expression changes have also been
observed in tumor xenografts in immune compromised mice treated with a hairpin-
polyamide (20).
In this study, our goal was to identify a Py-Im polyamide capable of affecting E2 stimulated
gene expression in breast cancer cells and characterize its activity in cell culture and in
tumor xenografts. To do this, we drew from an earlier study that reported a polyamide
targeted to the ERE consensus half site 5’-WGGWCW-3’ inhibited ERα binding to DNA in
cell-free systems (21). The DNA-binding affinity and specificity of the ERE-targeted
polyamide was characterized in this and other studies (21, 22). Since those publications, we
have improved the nuclear uptake of polyamides via modification of the C-terminus (23).
We have also demonstrated that polyamides are bioavailable after intravenous and
subcutaneous injection in mice (20, 24). We then decided to re-examine the activity of
polyamides capable of disrupting ERE-driven gene expression for use in vivo. We have
screened a focused library of polyamides for cytotoxicity and inhibition of luciferase activity
using the breast cancer cell line T47D-KBLUC that expresses luciferase under the control of
three tandem, canonical EREs (25). The most active polyamide identified, which the
consensus ERE, was further evaluated and showed a partial suppression of E2 stimulated
gene expression in cell culture. This polyamide circulated in mouse serum after
subcutaneous injection and demonstrated activity against E2-induced luciferase expression
in T47D-KBLUC tumor xenografts in mice with minimal host toxicity. A fluorescent analog
of this polyamide distributed widely in both tumor and mouse tissue after subcutaneous
injection.
Materials and Methods
Polyamide Synthesis and Characterization
The polyamides 1–5 were synthesized following previously published solid phase synthesis
protocols (26). Compound purities were confirmed by analytical HPLC and MALDI-TOF
MS. Melting temperature analysis was performed on a Varian Cary 100 spectrophotometer
with temperature control. Oligonucleotides (IDTDNA) were dissolved in 10 mM sodium
cacodylate, 10 mM KCl, 10 mM MgCl2 and 5 mM CaCl2 at pH 7.0 at a concentration of 2
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µM. Polyamides were added to oligo solution to a final concentration of 4 µM in 0.1%
DMSO. Oligonucleotides were annealed from 25–90°C and then back to 25°C at 5° C/min.
Subsequently, the temperature was elevated at a rate 0.5° C/min between 25–90° C. Melting
temperatures are defined as a maximum of the first derivative of absorbance at 260 nm over
the range of temperatures.
Cell culture and imaging
Cell lines used were purchased directly from ATCC and used within 6 months. No
subsequent authentications were done by the authors. All experiments were conducted with
T47D-KBLuc cells (ATCC), unless specifically mentioned otherwise. Cells were grown in
RPMI-1640 held at 37° C in 5% CO2. Media was supplemented with 10 % FBS and 1 %
Penicillin / Streptamycin. Before imaging, cells were plated in 35mm optical dishes
(MatTek) at 5×104 cells per dish in the presence of 10 nM E2. Cells were dosed with
polyamide for 24 hours. Cells were then washed twice with PBS and imaged on a confocal
microscope (Exciter, Zeiss) using a 63× oil immersion lens in a method previously
described. Confocal imaging was performed following our previously published protocols
(27, 28).
Tissue processing for fluorescence imaging
The tissue sections for fluorescent imaging were obtained by fixing the tumors in 10%
formaldehyde solution for 24 hours, and subsequent cryoprotection in 15 % sucrose (24h)
and 30 % sucrose (24h). The tumors were frozen in Tissue-Tek O.C.T. (Sakura Finetek) and
50 µm (for T47D-KBLuc xenograft) or 10 µm (for other tissues) sections were obtained
using a Leica CM 1800 cryotome. Imaging was performed as described above.
Cell toxicity and luciferase assays
T47D-KBLUC cells were plated at 3×103 cells/well in 96-well plates, incubated in standard
growth media containing 10 nM E2 for 48 hours and then dosed with medium containing 10
nM E2 and between 2 nM and 50 µM polyamides. The cells were then incubated for 96
hours and analyzed using either WST-1 assay (Roche) or luciferase assay system (Promega)
according to the manufacturers’ instructions.
Gene expression analysis by qRT-PCR
Cells were plated in 12 well-plates at 1.1×105 cells/well and incubated in the growth
medium supplemented with 10 nM E2 for 24 hours. Afterwards, medium was exchanged
with the growth medium supplemented with polyamides and 10 nM E2. RT-qPCR has been
performed according to previously established protocols (3–6). Confirmation of inhibition of
TFF1 expression by polyamides 1 – 4 was performed qRT-PCR was done following the
same timeline as cell toxicity and luciferase assays. Gene expression was normalized against
GUSB as housekeeping gene. All primers yielded single amplicons as determined by both
melting denaturation analysis and agarose gel electrophoresis. The following primer pairs
were used. GUSB: fwd. 5'-CTC ATT TGG AAT TTT GCC GAT T-3' rev. 5'-CCC AGT
GAA GAT CCC CTT TTT A-3'. DOK7: fwd. 5’-GAC AAG TCG GAG CGT ATC AAG-3’
rev. 5’-ATG TCC TCT AGC GTC AGG CT-3’. WT1: fwd. 5’-CAC AGC ACA GGG TAC
GAG AG-3’ rev. 5’-CAA GAG TCG GGG CTA CTC CA-3. TGFB2: fwd. 5’-CAG CAC
ACT CGA TAT GGA CCA-3’ rev. 5’-CCT CGG GCT CAG GAT AGT CT-3’.
Chromatin immunoprecipitation experiments
T47D-KBLUC cells were plated into 500 square centimeter plates and grown in RPMI-1640
with 10% FBS until 75% confluence was reached. Plates were washed with RPMI-1640
with charcoal treated 10% FBS and then the media replaced with RPMI-1640 with charcoal
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treated 10% FBS with 2 µM polyamide 1 and incubated for 48 hours. Plates were then
treated with 10 nM E2 or vehicle for 45 minutes. Crosslinked chromatin was obtained using
the 2-step crosslinking methods previously described (29). Chromatin was isolated and
sheared. Antibodies to ERα (AC-066-100, Diagenode) were used to immunoprecipitate
ERα-bound DNA fragments. Crosslinks were reversed, and PCRs using primers targeted to
the regions of interest were used to assess enrichment of bound fragments as compared to
negative controls. TFF1 promoter: fwd. 5’-TCA GAT CCC TCA GCC AAG AT-3’ rev. 5’-
TGG TCA AGC TAC ATG GAA GG-3’ Negative loci control. fwd. 5’-AAA GAC AAC
AGT CCT GGA AAC A-3’ rev. 5’-AAA AAT TGC TCA TTG GAG ACC-3’.
Circulation and toxicity in vivo
All animal experiments were conducted according to approved IACUC protocols at the
California Institute of Technology. Circulation studies were done as previously described
(30). Briefly, 120 nmol of polyamide 1 was injected subcutaneously into the right flank of
four female C57BL/6 mice in a total of 200 uL of a 20% DMSO/PBS vehicle. Blood was
collected retroorbitally at serial time points. Serum was treated with methanol, analyzed via
HPLC, and quantified against a standard curve of concentration versus peak area, all as
previously described to determine approximate serum concentrations (24). For toxicity
studies, five female C57BL/6 mice were injected with 20 nmol of polyamide 1 in a total of
200 uL of a 20% DMSO/PBS vehicle on days 1, 3, 5, 8, 10, 12, and then with 30 nmol on
days 15, 17, 19, 22, 24, 26 and were weighed prior to each treatment day. Mice were
euthanized if weight loss was >15% of initial body weight, if dehydration was over 10 %, or
moribund behavior was observed. None were observed in this experiment.
Xenografts
Engraftment of T47D-KBluc. Experiments were performed in appropriately shaved female
NSG mice (JAX) between 8 and 12 weeks of age. Cells were injected into the left flank area
of the animals as suspensions of 5.0×106 mL−1 in 50% RPMI 1640 growth medium and
50% matrigel, 200 µL per injection. Mice also received a subcutaneous E2 pellet (0.72 mg,
60 day slow release, Innovative Research of America, Sarasota, Florida) implanted into the
right flank on the day of engraftment. Treatment and tumor monitoring. Mice were treated
with either 25 nmoles of 1 or 50 nmoles of 5. For the short term and fluorescent imaging the
studies they were treated 8 days after engraftment, every second day for a total of 4
injections. For long term treatment, injections started 16 days after engraftment and were
continued twice a week for the following 4 weeks. Imaging was accomplished using the
IVIS imaging system (Caliper). The animals were anesthetized with 2–3 % isoflurane and
injected intraperitoneally with 150 µL of RediJect D-Luciferin (Caliper) and subsequently
transferred to the imaging chamber while isoflurane levels were reduced to 1–2.5 %. The
floor of the imager was heated to +37 °C to avoid animal hypothermia. Breathing frequency
was monitored and not allowed to drop below one per second, adjusting the isoflurane levels
accordingly at all times. Endpoint criteria and euthanasia. Animal endpoint criteria
encompassed weight loss of over 15 %, restriction of motoric function by the engrafted
tumor, dehydration of over 10 % and moribund behavior. Where appropriate, the animals
were euthanized by asphyxiation in a CO2 chamber. Tumor tissue harvest. Animals were
resected and tumors excised using standard forceps, scissors and surgical blades. The tumors
were weighed immediately afterwards. For studies with FITC-conjugate 5, resected tumor
tissue was homogenized via blunt force and then pushed through a microfilter to achieve
single cell suspensions which were plated on glass microscopy slides for 6 hours prior to
imaging using a Zeiss Exciter fluorescence confocal microscope.
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RNA-Seq sample preparation and data processing
Cells for gene expression analysis were plated in 10 cm diameter dishes at 1.1×106 cells/
dish and incubated in the growth medium supplemented with 10 nM E2 for 24 hours.
Afterwards, medium was exchanged with the growth medium supplemented with
polyamides and 10 nM E2 and incubated for 48 hours in 5% CO2 and 37°C. The RNA was
then harvested using an RNEasy kit (Qiagen). Subsequently, a Riboguard RNAse inhibitor
was added and samples were treated with TurboDNA Free DNAse (Ambion), according to
manufacturers’ instructions. RNA-Seq libraries were prepared using standard Illumina
reagents and protocols. Single read sequencing with the read length of 50 nucleotides were
performed on the Illumina HiSeq2000 sequencer, following manufacturers’ instructions,
producing 35–50 million reads per library. Sequencing data were mapped against the
combined human (hg19) transcriptome, using the Bowtie program package 0.12.7 (31) and
the refseq annotation. The open access processing package Cuffdiff was employed to
calculated differential gene expression. Inter-replicate statistical significance was calculated
with the DEseq module (32).
Results
Design of polyamides
We synthesized four eight-ring hairpin Py-Im polyamides to screen for activity against E2
stimulated gene expression (Figure 1, Supplementary Figure S1). Polyamide 1 targets 5’-
WGGWCW-3’, which is the half-site ERE consensus. Polyamide 2 was previously reported
to inhibit a subset of DHT-induced gene expression in cultured prostate cancer cells (11).
Polyamide 3 was recently characterized in cultured lung cancer cells and used to partially
abrogate TNF-stimulated transcription (12). Polyamide 4 targets the sequence 5’-
WGWCGW-3’. Polyamide 5 and 6 are FITC-conjugated analogs of 1 and 2respectively,
used to visualize cellular uptake and distribution in this study.
Evaluation of binding of polyamides to an ERE half site by DNA thermal denaturation
assays
Polyamides 1–4 were incubated with duplex DNA 5’-CGATGGTCAAGC-3’, which
contains an ERE half-site consensus, and melting temperatures measured (Figure 2A).
Duplex stabilization was greatest for 1a polyamide that was predicted to bind this sequence
based on established Py-Im polyamide pairing rules (6, 7). The other polyamides
demonstrated less stabilization of this duplex.
Luciferase activity and cytotoxicity in T47D-KBLUC cells
The ERα positive cell line T47D-KBLUC expresses luciferase under the control of three
tandem repeats of the sequence 5’-AGGTCACTTGACCT-3’ (25), which is the consensus
sequence for the ERα-DNA homodimer (Figure 2B). T47D-KBLUC cells were grown in
10% FBS/RPMI-1640 media with 10 nM E2 for 48 hours. Then, media was replenished
with varying concentrations of polyamides 1–4 for 96 hours. An extended incubation time
with E2 was used to approximate the in vivo condition of continued E2 circulation. Cell
proliferation and viability was assayed using WST-1 (Roche), and luciferase output was
measured (Figure 2C). Both luciferase output and proliferation were affected most by
treatment with 1 (IC50 0.47 µM for viability, 0.14 µM for luciferase suppression), and least
by 3 (IC50 > 2.5 and 1.5 µM, respectively). The representative data for luciferase and
WST-1 assay shown in supplementary figure S2. We identified TFF1 as one of the most
highly induced transcripts by E2 based on published reports (33).The effects of 1–4 no E2
stimulated TFF1 expression were measured to validate the luciferase screen. Polyamide 1
was again found most potent, although 2 and 4 demonstrated significant inhibition of TFF1
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as well (Figure 2D). Inhibition of TFF1 mRNA by 1 is dose responsive (Supplementary
Figure S3). In addition, 1 demonstrates significantly less toxicity to LNCaP, U251, and
A549 cell lines (Supplementary Figure S4), which have low expression of ER-α (34–37).
Chromatin immunoprecipitation of ERα at the TFF1 promoter after E2 stimulation of cells
pre-treated with 1 showed reduced occupancy as compared to vehicle treated cells
(Supplementary Figure S5).
Genome-wide polyamide effects on E2 induced gene expression
Effects of hairpin polyamide 1 at 0.3 and 1 µM on the transcriptome of E2 induced cells
were measured using RNA-Seq. Reads were mapped using Hg19 reference human genome
and data was analyzed using the Bowtie and CuffDiff packages (38). Only the genes with
fragments per kilobase of exon per million fragments mapped (FPKM) ≥ 20 and at least
two-fold change in gene expression upon treatment with either 1 or E2 were used in the
analysis (Supplementary Table S1). Among those genes, at 1.0 µM, 1 affected expression of
346 genes (0.7% of total) at least two-fold as compared to E2 treated control. Of these
genes, an equal number of genes were up- and down-regulated (173 in each case). At the
lower concentration of 0.3 µM, expression of 127 genes (0.3% of total) was affected at least
two-fold, and a majority of these genes (77 vs 50) were downregulated. At the same
threshold, E2 upregulated 1003 genes (2.0%) (Figure 3A) and downregulated 575 genes
(1.2%) (Figure 3B). A fraction of expression changes induced by E2 were reversed by 1
(Supplementary Table S2), and this fraction was greater for E2 repressed genes. Among E2
upregulated genes 43 (4.3%) were repressed by 1 at least two fold at 1.0 µM. Among those
575 genes that were downregulated by E2, 95 (16.5%) were de-repressed by 1 at 1.0 µM at
least two fold (Figure 3A–B). Overall, of the 346 genes affected by 1 at 1.0 µM, 138
(39.9%) represent genes whose up- or down-regulation by E2 was abrogated by polyamide
treatment. Genes whose expression was affected by 1 at a lower concentration (0.3 µM)
were largely a subset of the genes affected at 1.0 µM, 103 of which (81.1%) were affected
by 1 at both concentrations.
Further analysis was performed using Euclidian distance clustering with complete linkage
(Figure 3C). Interestingly, while the majority of E2 affected genes are not affected by 1out
of the top 50 genes most strongly affected by E2, 28 (56%) are inhibited at least two-fold,
and 38 out of 50 (78%) genes are inhibited at least 1.5-fold by 1 (Figure 3D).
Five transcripts were selected for verification by qRT-PCR and all five showed good
reproducibility of the expression changes seen by RNA-Seq (Figure 4). Four were
upregulated by E2 (AREG, DOK7, TFF1, WT1) and one downregulated by E2 (TGFB2).
Circulation and toxicity of polyamide 1 in mice
To assess serum concentrations of 1 after subcutaneous injection, four female C57BL/6 mice
were injected subcutaneously into the left flank with 120 nmol of 1 in a 200 µL 20% DMSO/
PBS vehicle. Serial serum samples were taken via retroorbital draw and processed by
methods previously described (30). Polyamide 1 was detectable in serum for up to 24 hours
after injections, and reached a maximum concentration of 3 µM at 6 hours after injection
(Supplementary Figure S6A). Toxicity after repeated injections of 1 was assessed by daily
weights and visual inspection of treated mice. Five female C57BL/6 mice were injected with
20 nmol of 1 subcutaneously to the left flank three times a week for two weeks without
measurable weight loss. The regimen was then increased to 30 nmol for two weeks, again
without measurable weight loss or changes in animal behavior (Supplementary Figure S6B).
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Effects on ERα mediated transcription in T47D-KBLUC tumor bearing mice after short-term
treatment
To measure the efficacy of 1 in vivo against E2-induced transcription, T47D-KBLUC cells
were engrafted into female nod-scid-gamma (NSG) immunocompromised mice
supplemented with a slow-release subcutaneous E2 pellet in the right flank to facilitate E2-
induced growth. After one week of growth, mice were imaged utilizing the IVIS imaging
system (Caliper) and stratified into groups of 12 mice each for vehicle and polyamide
treatment. Polyamide 1 (25 nmol) in 200 µL 20% DMSO/PBS was injected subcutaneously
into the left shoulder every other day for a total of four injections. Vehicle treated mice
received 20% DMSO/PBS alone. After three injections, mice were re-imaged. Luciferase
output increased an average of eight-fold for the vehicle treated mice and three-fold for the
mice treated with 1 (Figure 5A). Mice were euthanized the day following the fourth
injection for tumor resection. Tumors from vehicle treated mice were 71±12 mg and tumors
from polyamide treated mice 55 ±11 mg (Figure 5B), which does not explain the differences
seen in luciferase expression. Representative images of mice treated with 1 or vehicle at day
6 are shown (Figure 5C).
Effects on ERα mediated transcription in T47D-KBLUC tumor bearing mice after long-term
treatment
To investigate the effects of 1 in tumor bearing mice after extended treatment, T47D-
KBLUC cells were again engrafted into female NSG mice supplemented with a
subcutaneous E2 pellet in the right flank. Tumors were grown for nine days prior to
stratification of five mice each into polyamide 1 and vehicle treatment groups. Mice were
treated with vehicle or 25 nmol of 1 in 20% DMSO/PBS, subcutaneously into the left
shoulder twice a week for a course of 9 injections (25 days), beginning on day 16 after
engraftment (Figure 5D). Treated mice maintained their weights at >90% until the final days
of treatment when their weights decreased to >85% prior to euthanasia. Luciferase was
monitored weekly utilizing the IVIS imaging system. Luciferase output in the polyamide
treated mice was consistently lower than vehicle treated mice (Figure 6E). At the
experimental endpoint, tumors from vehicle treated mice were 165 ± 27 mg and tumors from
polyamide treated mice 128 ± 54 mg.
Tissue distribution of FITC-conjugated polyamide 5 in mice bearing T47D-KBLUC
xenografts
Py-Im polyamide 5 is a FITC labeled conjugate of hairpin 1 that was synthesized to evaluate
tissue and sub-cellular localization via fluorescence microscopy. T47D-KBLUC cells
cultured in vitro and then treated with 5 showed nuclear fluorescence similar to what has
been reported in other cell lines (27, 28) treated with FITC-conjugated polyamides in cell
culture (Supplementary Figure S7). An NSG mouse engrafted with T47D-KBLUC cells as
described in the previous section was treated with polyamide 5 in a manner identical to that
of 1except at a dose of 50 nmol per injection. After three injections, the mouse was
euthanized, the tumor resected, and internal organs dissected. Tissue was fixed,
cryoprotected, sectioned and imaged immediately. Fluorescence signal was evenly
distributed throughout multiple sections of the tumor xenograft. A representative section is
shown (Figure 6A). High magnification reveals nuclear localization in tumor tissue (Figure
6B). Sections of cardiac muscle show significant cytoplasmic fluorescence in a fibrous
pattern (Figure 6C). Sections of kidney and liver both show nuclear fluorescence
localization, with minimal cytoplasmic fluorescence (Figure 6D–E) Small bowel epithelia
show diffuse cellular fluorescence (Figure 6F).
To ensure that nuclear fluorescence in the xenografts was not an artifact of the fixation
process, we extracted live cells from T47D-KBLUC xenografted tumors from mice treated
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with 5 as above. In this experiment, cells were isolated via filtration and plated on
microscope slides, and incubated for six hours before imaging. Cells derived from the tumor
demonstrated nuclear staining in a pattern similar to that seen in the fixed tumor sections as
well as cultured cells treated with 5 in vitro (Supplementary Figure S8).
Discussion
In order for DNA-binding Py-Im polyamides to be considered for therapeutic application,
these molecules must possess favorable pharmacokinetic and pharmacodynamic properties
and exert a desired effect in target tissues. In this study, ERα-induced transcription in
xenografted breast cancer tumors was the target. A polyamide targeted to the ERE half site
5’-WGGWCW-3’ was identified from a focused screen for activity against ER mediated
transcription and cytotoxicity against ERα positive breast cancer cells. This polyamide was
further tested for its global effects on the transcriptome of E2 induced T47D-KBLUC cells.
Hairpin polyamide 1 demonstrated limited toxicity and circulated at therapeutic levels in
serum after subcutaneous injection. It also showed activity against ER driven luciferase
expression in xenografted tumors in immunocompromised mice. FITC-polyamide conjugate
5 shows widespread localization in body tissues including sections through the xenografted
tumor, which reveal nuclear fluorescence.
Suppression of ER-induced gene expression
We screened for both suppression of E2 induced luciferase expression and for anti-
proliferation by WST-1 assay using T47D-KBLUC cells. Polyamide 1 was the most active
by both measures while 3 was inactive by either measure. These molecules differ only at a
single atom, which represents the difference between a Py and Im heterocycle. Although
polyamides have been shown to have differing uptake properties depending on Py-Im
content and sequence (27, 28), the differences in activity in this series is likely not explained
by differing uptake efficiency since confocal microscopy of FITC-polyamide conjugates 5
and 6 are similar (Supplementary Figure 7).
Global effects on the E2 stimulated transcriptome
E2 exerts its effects through direct DNA binding and less frequently extranuclear pathways
that do not involve ERα-DNA binding (39). Our genome-wide transcriptome analysis
(Figure 4) revealed that a small fraction of gene expression changes induced by E2 treatment
is suppressed by polyamide 1. From a total of 1003 E2 up-regulated genes, only 43 (0.43%)
are repressed by 1 at 1.0 µM, and from a total of 575 E2 downregulated genes, 95 (16.5%)
were de-repressed. However, among the 50 genes most strongly either induced or repressed
by E2, a majority were significantly affected by 1. Among these top 50, 28 (56%) were
downregulated by 1 (1.0 µM) at least two-fold. At a lower cut-off of 1.5-fold, 38 (76%) of
E2 induced gene expression changes were abrogated by the action of 1 at 1.0 µM. Many of
these strongly E2-responsive genes play important roles in the development of tumors and
are therapeutically relevant. Among them is Wilms Tumor 1 (WT1), a gene originally
identified as a tumor suppressor (40), however more recently it has become apparent that
can also act as an oncogene (41). WT1 expression is detectable in 90% of breast cancers
(42) and high levels of WT1 expression are correlated with poor patient survival (43). TFF1
is a predictor for breast cancer patient survival (36). Transforming growth factor-β2 (TGF-
β2) was observed among the most strongly E2-repressed genes and was also over 3-fold de-
repressed by 1 at 1.0 µM. TGF-β2 is involved in cancer development that is also de-
repressed by traditional anti-estrogens (44). We conclude that 1 acts in an anti-estrogenic
fashion among genes that are most potently affected by E2, but is less active for the majority
of E2 responsive genes. If the mechanism by which 1 interferes with estrogen driven gene
expression is through direct interference with ER-DNA interfaces, we would not expect to
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affect ER-driven transcription at loci where ER signals through a tethering complex (45),
such as with Ap1 and Sp1. Indirect interactions between estrogen receptor and DNA through
tethering with other proteins offer a partial explanation for the limited number of ER driven
transcripts affected by 1.
Most transcripts affected by 1 are not explained on the basis of E2 antagonism; 295 genes
that are either up- or down- regulated by 1 at least 2-fold that are not explained by effects on
ER activity. Of these, 164 are up-regulated and 131 down-regulated by 1. To further
characterize these effects, we utilized the DAVID functional annotation tool (46, 47). For
the up-regulated transcripts, enriched biological processes include those involved with the
regulation of apoptosis and cell-death, as well as responses to endogenous and hormone
stimuli whereas downregulated genes suggested that 1 is involved in regulation of GTPase
mediated signal transduction and protein transport and biosynthesis (Supplementary Table
S3). The mechanisms of cell-death may include the inhibition of transcription (10, 11, 13,
15), but other DNA dependent processes may contribute, and are an area of current
investigation. Whether or not the effects of 1 on these biological processes are specific to
polyamide 1 or may represent a class-effect is unknown but is also under study.
Polyamide treatment suppresses E2 simulated luciferase expression in vivo
T47D-KBLUC cells were chosen as the cell line for our study based on previous work using
T47D cells as a model for ERα positive breast cancer. Both vehicle and polyamide treated
groups showed an increase in total luciferase expression from the baseline measurement
immediately prior to treatment on day 1. However, on day 6, after three sequential
injections, this increase was significantly blunted in the polyamide treated group as
compared to vehicle (from ~8-fold to ~3-fold), suggesting that 1 was able to reach sufficient
concentrations in tumor tissue to affect luciferase expression. The approximately 2.5-fold
difference in luciferase between polyamide treated and vehicle treated groups, if interpolated
to the in vitro data, suggest an approximate concentration of 0.3 µM within the xenograft
tissue. Tumor masses did not differ significantly between polyamide treated and vehicle
treated mice in this experiment. However, this six-day experiment may be too brief to
adequately assess effects on tumor growth.
Effects on tumor size
Although there are no published reports on the growth of T47D-KBLUC xenografts in mice,
data from parental T47D xenografts show a slow, linear growth pattern rather than
exponential (48). To better assay for antitumor activity of 1we conducted similar
experiments over a longer period of time. T47D-KBLUC xenografted tumors were grown
for two weeks prior to initiating treatment, and treatment with 1 was performed twice per
week for a total of four weeks. We observed no significant change in tumor size at the
experimental endpoint, although we found a sustained suppression of luciferase output in the
polyamide treated arm as compared to vehicle treated, consistent with our initial
observations. The IC50 for cytotoxicity of 1 in cell culture is 0.47 µM, which we believe to
be higher than the concentrations achieved within the tumor tissues in this study.
Tissue distribution of FITC conjugate 5 in mice after repeated subcutaneous injections
Fixed, frozen sections through multiple internal organs harvested from T47D-KBLUC
engrafted mice treated with 5 reveal widespread organ distribution of fluorescent signal, but
with differing patterns of fluorescence between tissues, and with little obvious systemic
toxicity. The tumor sections show nuclear fluorescence in a subcellular pattern that is similar
to what is observed in cell culture (Figure 6A). The liver and kidneys also demonstrate
strong nuclear fluorescence (Figure 6D–E), while sections through the intestinal epithelium
and cardiac muscle show predominantly cytoplasmic, and both cytoplasmic and nuclear
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fluorescence, respectively. A difference in the cellular uptake of polyamide-FITC conjugates
between cell types has also been observed in vitro (27). Recent work has shown that
polyamides can form aggregates in solution (49). Whether polyamide aggregation influences
distribution in vivo is unknown. Tissue-specific targeting of small molecule drugs is an area
of current investigation that may become relevant for this class of molecules as additional in
vivo experiments are planned.
Conclusion
Polyamide 1 delivered by subcutaneous injection in a simple DMSO/saline vehicle
distributed widely in host and tumor tissue and demonstrated adequate bioavailability to
affect luciferase expression in xenografted tumor tissue, with acceptable toxicity. Future
investigations will include optimization of polyamides for lower systemic toxicity without a
compromise in efficacy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Ball-and-stick models of polyamides 1–6 with DNA target sequences as follows: 1, 5’-
WGGWCW-3’; 2, 5’-WGWWCW-3’; 3, 5’-WGGWWW-3’; 4, 5’-WGWCGW-3’. 5 and 6
are FITC-analogs of 1 and 2, respectively, used for fluorescence microscopy experiments.
Chemical structures of 1–6 are in Supplementary Figure S1.
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Figure 2.
A, Thermal denaturation assays of a duplex DNA oligonucleotide containing a half site
ERE. Polyamide 1 demonstrates the most stabilization. B, Sequence of ERE-driven
luciferase in T47D-KBLUC cells. C, Polyamides 1–4 were screened for cytotoxicity and
suppression of ER-driven luciferase. Polyamide 1 is most potent by both measures.
Representative isotherms are displayed in Supplementary Figure S2. D, Polyamides dosed at
0.3 µM were screened for activity against TFF1 expression, a known ERE driven gene. The
relative activities of 1–4 approximately mirror what is seen in the luciferase assay at this
concentration. At higher concentrations (~1 µM), all 4 polyamides demonstrate activity.
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Figure 3.
RNA-seq global transcriptome analysis. All ratios are normalized to the induced control (10
nM E2). A, Venn diagrams show the overlap between genes upregulated by E2 at least two-
fold and genes downregulated by 1 at 0.3 µM or 1.0 µM. B, Venn diagrams for the overlap
of genes downregulated by E2 at least two-fold and de-repressed by 1 at 0.3 µM or 1.0 µM.
C, Hierarchical clustering (Euclidian distance, complete linkage) of genes changed at least
two-fold as compared to the induced state. D, 50 genes that were most changed by E2
induction were clustered (Eucludian distance, complete linkage). Of those genes 30 were
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upregulated and 20 were downregulated by E2. Fold-changes are relative to E2-induced
control.
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Figure 4.
Confirmation of genome-wide polyamide effects observed by RNA-seq. Five genes (four
induced and one repressed by estrogen) were interrogated. A, Relative mRNA levels of
selected genes measured by qRT-PCR. B, Relative mRNA expression values as measured
by fragments per kilobase of exon million (FPKM) from RNA-seq. Concentrations of 1 are
1.0 µM and 0.3 µM.
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Figure 5.
Xenograft studies. A, Treatment of T47D-KBLUC bearing mice with 1 results in
suppression of ER-driven luciferase. **p<0.01. n = 12 mice per group. Errors are 95% CI.
B, Tumors masses at experimental endpoint were vehicle: 71±12 mg (95% CI); 1: 55 ±11
mg (95% CI). C, Representative luciferase output of vehicle and treated mice on day 6. D,
Treatment schedule for extended time-course experiments with normalized mouse weights
over time. Arrows indicate treatment days. E, Luciferase signal for polyamide 1 and vehicle
treated groups. Error bars are standard deviations. Mean tumor masses at the endpoint for
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animals treated with vehicle is 165±27mg (95% CI) and for animals treated with 1 is
128±54mg (95% CI).
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Figure 6.
Tissue frozen sections of tissue extracted from xenograft bearing mouse treated with 5. A,
FITC-labeled Py-Im polyamide 5 distributes widely in sections of the T47D-KBLUC tumor
xenograft. B, High magnification shows nuclear localization of 5 in tumor cells. C, Cardiac
muscle sections show a fibrous pattern of fluorescence in the cytoplasm as well as nuclear
staining. D, Kidneys demonstrate nuclear localization of 5. E, Liver sections show nuclear
localization of 5. F, Bowel epithelia show cytoplasmic fluorescence.
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